Core Insights - Guangkang Biotech (300804) reported a 9.41% year-on-year decline in Q3 revenue, totaling 151 million yuan, while net profit attributable to shareholders increased by 236.87% to 5.83 million yuan [1] - For the first three quarters, the company achieved a revenue of 550 million yuan, reflecting a 13.53% year-on-year growth, and a net profit of 34.84 million yuan, up 47.1% year-on-year [1] Financial Performance - Q3 revenue: 151 million yuan, down 9.41% year-on-year [1] - Q3 net profit: 5.83 million yuan, up 236.87% year-on-year [1] - Year-to-date revenue: 550 million yuan, up 13.53% year-on-year [1] - Year-to-date net profit: 34.84 million yuan, up 47.1% year-on-year [1] Strategic Developments - The company announced plans to establish a joint venture, Shaoguan Henong Crop Technology Co., Ltd., with natural persons Wang Shiyin, Wu Guanghui, and Che Lin [1] - The registered capital of the joint venture is 3 million yuan, with Guangkang Biotech's subsidiary, Guangzhou Henong, contributing 2.55 million yuan, representing 85% of the total investment [1]
广康生化：第三季度净利润同比增长236.87%